INVO Fertility, Inc (NASDAQ:IVF) Stock Short Interest Report for September

INVO Fertility, Inc (NASDAQ:IVF) was the recipient of a large decrease in short interest in September. As of September 30th, there was short interest totaling 50,118 shares, a decrease of 74.1% from the September 15th total of 193,695 shares. Based on an average trading volume of 151,104 shares, the days-to-cover ratio is presently 0.3 days. Approximately 2.0% of the company’s stock are short sold.

INVO Fertility Stock Performance

NASDAQ:IVF traded down $0.00 during trading on Monday, reaching $0.73. The company’s stock had a trading volume of 93,272 shares, compared to its average volume of 1,922,187. The firm has a market cap of $1.82 million, a price-to-earnings ratio of -0.02 and a beta of 2.39. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.67 and a current ratio of 0.71. The firm has a 50 day moving average of $0.99 and a 200-day moving average of $1.46. INVO Fertility has a 12 month low of $0.71 and a 12 month high of $84.40.

INVO Fertility (NASDAQ:IVF) last released its earnings results on Friday, August 14th. The company reported $0.35 EPS for the quarter. The company had revenue of $2.18 million for the quarter. INVO Fertility had a negative return on equity of 85.54% and a negative net margin of 116.29%.

Analysts Set New Price Targets

Several brokerages have recently commented on IVF. Weiss Ratings reiterated a “sell (e+)” rating on shares of INVO Fertility in a report on Monday, August 3rd. Wall Street Zen upgraded shares of INVO Fertility to a “hold” rating in a report on Saturday, August 29th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, INVO Fertility has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

INVO Fertility Company Profile

INVO Fertility, Inc (NASDAQ: IVF) is a fertility-care company focused on expanding access to in vitro fertilization (IVF) through its INVO Procedure and related medical technology. The company develops, manufactures and commercializes INVOcell, an FDA-cleared medical device designed to provide a controlled environment for fertilizing and incubating embryos inside a woman’s body, as an alternative to conventional laboratory-based embryo culture.

The INVO Procedure uses INVOcell as part of an assisted-reproductive treatment process that can be offered by fertility specialists and clinics.